Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma This series of 3 studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results